KALV — Kalvista Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.42 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.51% | ||
| Return on Equity | -139.3% | ||
| Operating Margin | -107.13% | ||
Financial Summary
| Year End 30th Apr | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 242.2 | 242.2 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Directors
- Martin Edwards NEC (65)
- Thomas Crockett CEO
- Benjamin Palleiko CFO (55)
- Michael Smith SVP (42)
- Edward Feener CSO (60)
- Christopher Yea OTH (56)
- Albert Cha IND (49)
- Brian Pereira IND (62)
- Daniel Soland IND (63)
- Nancy Stuart IND (63)
- Edward Unkart IND (71)
- Last Annual
- April 30th, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- March 26th, 2004
- Public Since
- April 9th, 2015
- No. of Shareholders
- 15
- No. of Employees
- 275
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 53,240,888
- Address
- 200 CROSSING BOULEVARD, FRAMINGHAM, 01702
- Web
- https://www.kalvista.com/
- Phone
- +1 3025310855
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KALV
Similar to KALV
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Kalvista Pharmaceuticals share price?
As of Today at 12:32 UTC, shares in Kalvista Pharmaceuticals are trading at $26.79. This share price information is delayed by 15 minutes.
How has the Kalvista Pharmaceuticals share price performed this year?
Shares in Kalvista Pharmaceuticals last closed at $26.79 and the price had moved by +134.59% over the past 365 days. In terms of relative price strength the Kalvista Pharmaceuticals share price has outperformed the S&P500 Index by +82.15% over the past year.
What are the analyst and broker recommendations for Kalvista Pharmaceuticals?
The overall consensus recommendation for Kalvista Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kalvista Pharmaceuticals dividend yield?
Kalvista Pharmaceuticals does not currently pay a dividend.
Does Kalvista Pharmaceuticals pay a dividend?
Kalvista Pharmaceuticals does not currently pay a dividend.
When does Kalvista Pharmaceuticals next pay dividends?
Kalvista Pharmaceuticals does not currently pay a dividend.
How do I buy Kalvista Pharmaceuticals shares?
To buy shares in Kalvista Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kalvista Pharmaceuticals?
As of the previous close price of $26.79, shares in Kalvista Pharmaceuticals had a market capitalisation of $1.43bn.
Where are Kalvista Pharmaceuticals shares listed?
Here are the trading details for Kalvista Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KALV
What kind of share is Kalvista Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Kalvista Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kalvista Pharmaceuticals share price forecast for 2026?
The analyst consensus target price for shares in Kalvista Pharmaceuticals is $29.88. That is 11.53% above the last closing price of $26.79.
Analysts covering Kalvista Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.44 for the next financial year.
Find out moreWhat is the trend in the Kalvista Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kalvista Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +83.48%.
As of the last closing price of $26.79, shares in Kalvista Pharmaceuticals were trading +67.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kalvista Pharmaceuticals PE Ratio?
The Kalvista Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 6.42. The shares last closed at $26.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals' management team is headed by:
- Martin Edwards - NEC
- Thomas Crockett - CEO
- Benjamin Palleiko - CFO
- Michael Smith - SVP
- Edward Feener - CSO
- Christopher Yea - OTH
- Albert Cha - IND
- Brian Pereira - IND
- Daniel Soland - IND
- Nancy Stuart - IND
- Edward Unkart - IND